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Abstract
 
Inflammatory arthritis is associated with the release of a network of key cytokines. In T cell re-
ceptor transgenic K/BxN mice interleukin (IL)-1 plays a key role in joint swelling and destruc-
tion, as suggested by the ability of anti–IL-1receptor (IL-1R) antibody treatment to delay the
onset and slow the progression of this disease. This mechanism is dependent on the signaling
pathway intermediary myeloid differentiation factor 88 (MyD88), such that neither IL-1R nor
MyD88-deficient mice developed visually detectable synovitis after transfer of arthritogenic
sera. The Toll-like receptors (TLRs) share the same signaling pathway through MyD88 as the
IL-1R. The administration of a TLR-4 ligand, lipopolysaccharide, concomitant with arthritogenic
serum in IL-1 receptor–deficient mice resulted in acute paw swelling, but not in MyD88-defi-
cient mice. Also, serum transferred arthritis was not sustained in TLR-4 mutant mice compared
with controls. These results suggest that innate immune functions via TLR-4 might perpetuate
inflammatory mechanisms and bypass the need for IL-1 in chronic joint inflammation.
 
Key words: animal model • lipopolysaccharide • rheumatoid arthritis • autoantibody • 
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Introduction
 
In autoimmune inflammatory joint disease there might be a
complex interplay between genetics, immune stimulation
and environmental factors. The role of the environment
might come into play through the interaction of the innate
immune system and pattern-recognition receptors (PRRs).
Recently, a family of Toll-like receptors (TLRs) has been
identified as PRRs in mammals that serve to recognize
pathogen-associated molecular patterns (PAMPs; references
1 and 2). Microbial products such as LPS or peptidoglycan
(PG) function as ligands for TLR-4 (3) and –2 (1), respec-
tively. Recognition of these ligands by the innate immune
system leads to a cascade of events including the release of
cytokines and activation of antigen-presenting cells. Hence,
TLR-signaling might potentiate the priming milieu of the
adaptive immune system and perpetuate inflammation in a
T cell–independent manner.
Innate immune mechanisms have been implicated in es-
tablishing and propagating synovitis (for a review, see refer-
ence 4). In mice the ability of TLR signaling to lead to
destructive arthritis has been demonstrated by direct in-
traarticular injection of TLR ligands (TLR-Ls; references 5
and 6). In addition subclinical arthritis has been aggravated
by systemic injection of LPS or IL-1 (7). Although the
TLRs differ in their extracellular domain structure from the
cytokine receptors for IL-1 and IL-18, similar cytoplasmic
domains allow TLRs to use the same signaling molecules.
This pathway includes myeloid differentiation factor 88
(MyD88), which is an adaptor protein that links the IL-1
receptor to IL-1R–associated protein kinase (IRAK), a
serine-threonine kinase (8). Upon ligand binding to the
IL-1R, IRAK is phosphorylated, subsequently dissociates
from the receptor complex, and associates with TNF re-
ceptor-associated factor (TRAF)6 (9). This process results
in the activation of two different pathways that involve the
c-Jun NH2-terminal kinase (JNK), and p38 mitogen-acti-
vated protein kinase (MAPK) family and the Rel family
transcription factor nuclear factor (NF)-
 
 
 
B. Consequently
MyD88
 
 
 
/
 
 
 
 mice respond poorly if at all to IL-1, IL-18,
LPS, or other microbial cell wall components (8, 10).
IL-1 is a critical cytokine in erosive arthritis (11–13).
Given that the IL-1R and the TLR signaling pathways
converge on MyD88 we hypothesized that MyD88 activa-
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tion could occur through either IL-1R or TLR stimulation
leading to bone erosions and joint inflammation. To test
this hypothesis we used the transgenic K/BxN model of
spontaneous arthritis or the passive transfer of arthritis, us-
ing serum from K/BxN mice. Disruption of IL-1R signal-
ing in transgenic K/BxN mice by anti–IL-1R antibody
treatment diminished the extent of spontaneous disease.
Concordantly, IL-1R
 
 
 
/
 
 
 
 and MyD88
 
 
 
/
 
 
 
 mice did not de-
velop arthritis after serum transfer. However, coadministra-
tion of the TLR-4 ligand, LPS, and K/BxN serum did in-
duce paw swelling in IL-1R
 
 
 
/
 
 
 
, but not MyD88
 
 
 
/
 
 
 
 mice.
Furthermore, mice that are mutant in TLR-4 had a short-
ened course of paw swelling after serum transfer. These
data suggest that TLR signaling might additionally activate
MyD88 and perpetuate joint inflammation.
 
Materials and Methods
 
Mice.
 
KRN T cell receptor (TCR) transgenic mice were a
gift from Drs. D. Mathis and C. Benoist (Harvard Medical
School, Boston, MA) and Institut de Génétique et de Biologie
Moléculaire et Cellulaire (Strasbourg, France; reference 14), and
were maintained on a C57Bl/6 background (K/B). Arthritic
mice were obtained by crossing K/B with NOD/Lt (N) animals
(K/BxN). Progeny bearing the V
 
 
 
6 transgenic TCR were iden-
tified at 2–3 wk of age by cytofluorometry of peripheral blood
lymphocytes using anti-CD4 PE (Caltag) and anti-V
 
 
 
6 FITC
(BD Biosciences) labeled antibodies. C57Bl/6, IL-1R
 
 
 
/
 
 
 
, C3H/
HeJ, C3H/HeOU, and NOD/Lt mice were purchased from The
Jackson Laboratory. MyD88
 
 
 
/
 
 
 
 mice were a generous gift of Dr.
Akira (Osaka University, Osaka, Japan; reference 8). The mice
were bred and maintained under standard conditions in the Uni-
versity of California, San Diego Animal Facility that is accredited
by the American Association for Accreditation of Laboratory An-
imal Care. All animal protocols receive prior approval by the in-
stitutional review board.
 
Antibody Inhibition.
 
Endotoxin and azide free preparations of
anti–IL-1 receptor antibody (clone 35F5; BD Biosciences) and rat
IgG (Sigma-Aldrich) were diluted in sterile PBS and 150 
 
 
 
g of
antibody was injected intraperitoneally into young K/BxN mice
on Monday, Wednesday, and Friday of each week. This dose was
selected based on a previous report in which the same antibody
clone abrogated collagen induced arthritis at 100 and 200 
 
 
 
g
doses (15).
 
Serum Transfer and Arthritis Scoring.
 
Arthritic adult K/BxN
mice were bled and the sera were pooled. Recipient mice are in-
jected with 100 
 
 
 
l intraperitoneally on days 0 and 2. Some
groups of mice also received 50 
 
 
 
g of LPS (Sigma-Aldrich) de-
rived from 
 
Escherichia coli
 
 serotype O111:B4 in sterile PBS intra-
peritoneally. For each swollen paw 1 point was given, resulting in
a maximum score of 4 per mouse. Ankle thickness was measured
with a caliper (Manostat) in mm.
 
Histology.
 
Whole knee joints and hind paws were fixed in
10% formalin, decalcified, trimmed, and embedded. Sections
were prepared from the tissue blocks and stained with hematox-
ylin and eosin (H&E) (Comparative Biosciences). Histopatho-
logical scoring was performed as described below. Knees of ar-
thritic mice were given scores of 0–5 for inflammation,
according to the following criteria: 0 
 
 
 
 normal; 1 
 
 
 
 minimal in-
filtration of inflammatory cells in periarticular area; 2 
 
 
 
 mild in-
filtration; 3 
 
 
 
 moderate infiltration; 4 
 
 
 
 marked infiltration; and
5 
 
 
 
 severe infiltration. Knees of arthritic mice were given scores
of 0–5 for bone resorption, according to the following criteria:
0 
 
 
 
 normal; 1 
 
 
 
 minimal (small areas of resorption, not readily
apparent on low magnification); 2 
 
 
 
 mild (more numerous areas
of resorption, not readily apparent on low magnification, in tra-
becular or cortical bone); 3 
 
 
 
 moderate (obvious resorption of
trabecular and cortical bone, without full-thickness defects in the
cortex; loss of some trabeculae; lesions apparent on low magnifi-
cation); 4 
 
 
 
 marked (full-thickness defects in the cortical bone
and marked trabecular bone loss, without distortion of the profile
of the remaining cortical surface); and 5 
 
 
 
 severe (full-thickness
defects in the cortical bone and marked trabecular bone loss,
with distortion of the profile of the remaining cortical surface).
Each slide was scored by two independent observers and the av-
erage score was used.
 
ELISA.
 
Lapine glucose-6-phosphate isomerase (G6PI) type
IV and XI (Sigma-Aldrich) were coated on high affinity 96-well
ELISA plates (Costar) at 10 
 
 
 
g/ml in PBS. Plates were then
blocked with PBS 1% BSA. Anti–glucose-6-phosphate isomerase
antibodies in sera were detected with alkaline phosphatase la-
beled goat anti–mouse IgG (Southern Biotechnology Associates,
Inc.) followed by incubation with 
 
p
 
-nitrophenyl phosphate sub-
strate (Sigma-Fast; Boehringer). Absorption was measured at 405
nm. The pool of injected sera was used as standards, arbitrarily
set at 10
 
6
 
 units of IgG. Data were analyzed using DeltaSOFT II
v. 3.66 (Biometallics).
 
Results
 
IL-1 Signaling Is Critical to Development of Serum Trans-
ferred Arthritis.
 
Mice that express both the KRN TCR
and the IA
 
g7
 
 MHC class II allele (K/BxN) develop chronic
symmetric joint disease with pannus formation, and de-
structive bone and cartilage erosion of predominantly the
distal joints uniformly after 5 wk of life (14). To test the
role of IL-1 in the development of arthritis in the K/BxN
mouse model, transgenic mice were treated with anti–IL-1
receptor antibody or control rat antibody starting at the
time of weaning. Within 5 wk the group that received the
control antibody had all developed severe arthritis. In
the same time interval only half of the anti–IL-1R–treated
mice developed mild clinical disease (Fig. 1).
The arthritis in these mice usually develops in parallel
with the production of anti-G6PI antibodies. At the end of
the study the mice were bled and the anti-G6PI antibody
titers were measured (Fig. 1 C). Although it appeared that
there was a slight trend toward higher titers in the rat IgG–
treated control group, there was no statistical difference
(P 
 
  
 
0.29). The chief influence of IL-1 in other murine
models of inflammatory arthritis appears to be in the latter
or destructive phase, rather than in acute synovitis. All of
the mice in this study had their knees examined for histo-
logic evidence of synovial inflammation and bone erosion.
The anti–IL-1R treatment group had only occasional
pockets of inflammatory cell infiltration and fewer areas of
bone destruction (Fig. 1 D).
 
Transfer of Arthritis by K/BxN Sera Is IL-1R and MyD88
Dependent.
 
The anti–IL-1–treated K/BxN transgenic
mice had a trend toward decreased anti-G6PI antibody
production, which might explain the decreased severity ofT
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arthritis. Therefore, the role of IL-1 was further tested in a
serum transfer model, where a fixed dose of autoantibody-
containing serum is administered. The IL-1 receptor–defi-
cient mice that received K/BxN serum failed to develop
arthritis (Fig. 2 A). As the IL-1 signaling pathway includes
MyD88, these genetically mutated mice were evaluated.
Similar to the IL-1R
 
 
 
/
 
 
 
 mice, MyD88
 
 
 
/
 
 
 
 mice did not
develop disease after arthritogenic serum transfer (Fig. 2 B).
The knees of sera injected wild-type control, IL-1R
 
 
 
/
 
 
 
,
and MyD88
 
 
 
/
 
 
 
 mice were examined for the evidence of
subclinical inflammation and erosions by histology. There
were minimal findings in the IL-1R
 
 
 
/
 
 
 
 and MyD88
 
 
 
/
 
 
 
mice compared with the severe erosive destruction seen in
the C57Bl/6 control group (see Fig. 5 A).
 
TLR-4 Signaling Modulates Arthritis.
 
The lack of arthri-
tis in the MyD88-deficient mice suggested that other re-
ceptors, which use this signaling mediator, like TLR-4,
might have an effect on the transfer of arthritis. C3H/HeJ
mice have a missense mutation in the third exon of the
TLR-4 gene, predicted to substitute proline with histidine
at position 712 of the polypeptide chain (3). K/BxN serum
given to C3H/HeJ mice resulted in acute paw swelling.
However, the paw swelling subsided more rapidly than in
C3H/HeOU control mice, which do not share the TLR-4
defect (Fig. 3).
 
TLR-4 Ligand Stimulation Circumvents a Requirement for
IL-1R Signaling.
 
As the TLR-4 mutant mice resolved
their paw swelling more rapidly after serum transfer, a
complementary approach was used to evaluate the effect of
TLR-4 signaling in the serum transfer model. Mice were
given a systemic TLR-4 ligand, LPS, on day 0 concur-
rently with K/BxN sera. In C57Bl/6 mice this regimen did
not result in accelerated arthritis. However, the administra-
tion of LPS to IL-1 receptor–deficient mice resulted in ar-
thritis similar to wild-type controls (Fig. 4). The lack of ar-
thritis induction in the MyD88-deficient mice suggested
that the LPS signaled through this pathway bypassing the
requirement for IL-1R signaling (Fig. 4). Concordantly
there was histologic evidence of increased inflammatory in-
filtration and bone erosion in IL-1R
 
 
 
/
 
 
 
 mice that received
LPS, which was not appreciated in the MyD88
 
 
 
/
 
 
 
 mice
(Fig. 5, A–C).
Figure 1. Anti–IL-1R antibody treatment delays the onset of arthritis
in K/BxN mice. At  3 wk of age transgenic K/BxN mice were started
on a course of either 150  g anti-IL-1R antibody (n   8) or isotype con-
trol antibody (n   8) intraperitoneally three times a week. Ankle thick-
ness was measured with a caliper (A) and the arthritis was clinically scored
(B) for the isotype control group (squares) and the anti–IL-1R antibody
group (circles), respectively. (C) At the end of the study the mice were
bled and the sera assayed for anti-G6PI (P   0.29 by Student’s t test). (D)
The hind limbs of all mice were removed and one knee from each mouse
was prepared for histologic scoring. Shown are the average inflammation
and erosion scores   SEM.
Figure 2. Transfer of arthritis by K/BxN sera is IL-1R and MyD88 de-
pendent. Adult K/BxN mice were bled and the sera pooled. Adult
C57Bl/6 (square), IL-1R /  (triangle), and MyD88 /  (circle) mice were
injected on days 0 and 2 with 100  l of pooled sera intraperitoneally. Ar-
thritis was clinically scored (B) and ankle thickness was measured with a
caliper (A). The means of 3–4 mice per group   SEM are shown.
Figure 3. TLR-4 signaling modulates antibody-mediated arthritis.
Adult K/BxN mice were bled and the sera pooled. C3H/HeJ (TLR-4
mutant; diamond) and C3H/HeOu (square) mice were injected on days 0
and 2 with 100  l of pooled sera intraperitoneally. Arthritis was clinically
scored (B) and ankle thickness was measured with a caliper (A). The
means of four mice per group   SEM are shown. Days when C3H/HOu
mice have significantly greater paw swelling than are noted (*), (P   0.05
by Student’s t test).T
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Discussion
 
Much interest has been raised by the KRN model of
spontaneously occurring erosive arthritis. In this model a
single autoreactive T cell receptor escapes negative selec-
tion in mice bearing a specific MHC class II allele, IA
 
g7
 
(14). In the periphery these T cells are able to promote a
breach in B cell tolerance and high levels of anti–glucose-
6-phosphate isomerase are secreted (16). The accumulation
of these autoantibodies in the serum then results in a de-
structive and erosive arthritis similar to that seen in human
rheumatoid arthritis (RA). The adoptive transfer of the se-
rum from these mice results in the generation of arthritis in
most recipient strains (14, 17). In previous reports key fac-
tors involved in developing arthritis after serum transfer in-
cluded the alternate complement pathway, Fc
 
 
 
 receptors,
and subsets of Fc
 
 
 
 receptor bearing cells (17–22). In the
K/BxN serum transfer the IL-1R was also found to play a
critical role in paw swelling (20).
Using this model we describe the potential for signaling
through the TLRs to circumvent the role of a key cyto-
kine, namely IL-1. The TLR family members have been
shown to trigger responses primarily to microbial compo-
nents. The specificities of some of the family members have
been elucidated. In particular TLR-2 and TLR-4 have
been shown to be essential for the recognition of distinct
bacterial cell wall components (3, 23). Microbial products,
however, are not specifically required for TLR signaling, as
mammalian ligands have also been identified for TLR-4.
Amongst these ligands heat shock protein (HSP)60 (24),
HSP70 (25), and fibronectin (26) are abundantly present in
the joint, and thus might be instrumental in perpetuating
synovial inflammation.
There is growing evidence that the signaling pathways
associated with each TLR are not identical and might,
therefore, result in different biological responses. Studies in
MyD88
 
 
 
/
 
 
 
 macrophages have suggested differences be-
tween TLR-2 and TLR-4 signaling (10, 27). MALP acti-
vation of NF-
 
 
 
B and MAPK, which is mediated by
TLR-2, is completely abolished in both TLR-2
 
 
 
/
 
 
 
 and
MyD88
 
 
 
/
 
 
 
 macrophages. However, LPS activates NF-
 
 
 
B,
and JNK and p38 in MyD88
 
 
 
/
 
 
 
 macrophages, albeit with
delayed kinetics (10). This suggests that a MyD88-indepen-
dent pathway(s) can mediate NF-
 
 
 
B, JNK, or p38 activa-
tion after TLR-4 signaling. In the serum transfer model,
however, LPS failed to induce inflammation in the
MyD88
 
 
 
/
 
 
 
 mice, suggesting that this pathway was the
dominant one.
Exposure to environmental pathogens might shape the
subsequent adaptive immune response and might also sus-
tain antigen-specific responses by recruiting and triggering
the activity of monocytes and macrophages in the area ex-
posed to microorganisms. The innate immune system
might “prime” the target organ to be receptive to damage
from further insult, as might be the case in adjuvant and
collagen induced arthritis where CFA is used. Alterna-
Figure 4. TLR-4 ligand stimulation circumvents re-
quirement for IL-1R signaling. Adult K/BxN mice were
bled and the sera pooled. Adult were injected with 100  l
of pooled sera intraperitoneally on days 0 and 2. In addi-
tion, some groups also received an injection of 50  g LPS
intraperitoneally on day 0. C57Bl/6 mice treated with sera
are presented as a positive control in each experiment. (A
and B) C57Bl/6 treated with sera (closed circle), and LPS
and sera (open circle); (C and D) C57Bl/6 treated with
sera (closed circle) and IL-1R /  mice treated with sera
and LPS (open square); and (E and F) C57Bl/6 treated
with sera (closed circle), MyD88 /  mice treated with LPS
and sera (open triangle) and sera alone (closed triangle).
Arthritis was clinically scored and ankle thickness was mea-
sured with a caliper. The means of 3–4 mice per group  
SEM are shown.
Figure 5. Inflammatory infiltration and  bone
erosion in IL-1R /  mice treated with LPS and
K/BxN serum. (A) One knee from each of the
mice above was prepared for histologic scoring.
Shown are the average inflammation and erosion
scores    SEM. The inflammation and erosion
scores were significantly greater in the C57BL/6
than the MyD88 /  or IL-1R /  groups (P  
0.005 by Student’s t test). (B) Shown is an example
of a serum treated IL-1R /  mouse knee at the site
where the cartilage meets the bone. The cartilage is
smooth and the synovium is a single cell layer. (C) In IL-1R /  mice that were treated with LPS and K/BxN sera bone erosions and remodeling were
noted. The scalloped edges of the synovium invading the bone can be seen (arrow). B and C are 100  original magnification. For orientation the s over-
lies synovium, b designates bone, and c indicates cartilage.T
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tively, antigen-independent release of IL-1 and TNF  by
TLR exposed synovial macrophages could perpetuate fi-
broblast proliferation and increase synoviocyte secretion of
IL-6, GM-CSF, and collagenase. In recent clinical trials bi-
ologic blockade of IL-1 or TNF  was not universally ef-
fective (28–30). In these patients with established rheuma-
toid arthritis the redundancy in the innate signaling
receptors might make them refractory to treatments target-
ing one ligand. Disruption of intraarticular TLR signaling
might provide an additional therapeutic modality for pa-
tients with refractory RA.
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